Indeed, PD-L1 positivity can be influenced by different aspects of the IHC assay that is being used, including the antibody clone (SP142 vs. 22C3), the staining protocols and platforms (Ventana vs. Dako), the scoring algorithms (immune cells only for SP142 vs. immune and tumor cells for 22C3), and the threshold used for positivity (Combined Positive Score (CPS) ≥10 vs. immune cells (IC) ≥1%). This evidence concerns the gene CD274 and neoplasm.